Third Rock's Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease

Kyle Blankenship

When Ambys Medicines, a Third Rock Ventures-backed regenerative play, launched in 2018, it came with some serious fanfare for its liver disease-focused approach. Now, after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Third Rock's Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Third Rock­'s Am­bys clos­es a megaround with the clin­ic still a ways off for its re­gen­er­a­tive cells for liv­er dis­ease

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Third Rock's Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease